國家衛生研究院 NHRI:Item 3990099045/3580
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 915536      Online Users : 1270
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/3580


    Title: Overexpression of cytochrome P450 1B1 in advanced non-small cell lung cancer: A potential therapeutic target
    Authors: Su, JM;Lin, P;Wang, CK;Chang, H
    Contributors: Division of Environmental Health and Occupational Medicine
    Abstract: Background: The association of aryl hydrocarbon receptor (AhR) overexpression with cytochrome P450 1B1 (CYP1B1) expression is commonly detected in non-small cell lung cancer (NSCLC). In vitro and animal studies have shown an interaction between AhR and p53, or the epidermal growth factor receptor (EGFR). The clinical importance of AhR or CYP1B1 overexpression, however, as well as the relationship between AhR and p53 or EGFR in lung carcinomas, remains unclear. Patients and Methods: Immunohistochemistry for AhR, CYP1B1, EGFR and/or p53 expression was performed on two tissue microarrays containing 152 NSCLC specimens. Results: High levels of CYP1B1, EGFR and p53 expression were more prevalent in stage-IV disease than in earlier stages (OR, 6.0; 95% C.I., 2.25-15.90), whereas AhR was not. The AhR expression, but not CYP1B1, was associated with both the EGFR (p=0.040) and p53 expression (p=0.026). The expression of AhR and CYP1B1 did not affect the survival of NSCLC patients. Conclusion: CYP1B1, EGFR and p53 overexpression are considered to be aggressive biomarkers for NSCLC, indicating that early-staged patients warrant an aggressive treatment when these factors are overexpressed in the cancer cells.
    Date: 2009-02
    Relation: Anticancer Research. 2009 Feb;29(2):509-515.
    Link to: http://ar.iiarjournals.org/content/29/2/509.abstract
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0250-7005&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000263731300009
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=61449200566
    Appears in Collections:[Pinpin Lin] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    SCP61449200566.pdf603KbAdobe PDF685View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback